Scientist working in the laboratory
Scientist working in the laboratory
Genetic Leap, Lilly partner to expedite genetic medicine development with AI
The collaboration will leverage Genetic Leap’s RNA-targeted AI platform to create genetic medicines against selected targets.
AI and RNA genetic-medicine company Genetic Leap is teaming up with pharma giant Eli Lilly to develop genetic medicine therapeutics.
According to the two companies, the partnership expands on a pilot program utilizing Genetic Leap’s RNA-targeted AI platform, designed to produce oligonucleotide drugs counter to targets chosen by Lilly in crucial therapeutic areas.
Lilly will provide Genetic Leap with as much as $409 million dollars in upfront commercial, development, regulatory and clinical payments and tiered royalties.
